Efficacy and safety of radioimmuno-therapy with yttrium 90 ibritumomab tiuxetan (Zevalin)

Mary Beth Riley*, Leo I. Gordon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Objectives To detail recent developments pertaining to the efficacy and safety of radioimmunotherapy with yttrium 90 (90Y) ibritumomab tiuxetan for patients with B-cell non-Hodgkin's lymphoma (NHL). Data sources Published clinical trials of 90Y ibritumomab tiuxetan and secondary literature on radioimmunotherapy and NHL. Conclusion Yttrium 90 ibritumomab tiuxetan is safe and effective in the indicated population. It has a good safety profile and is generally well tolerated. It is not associated with the adverse events from conventional chemotherapy and external beam radiation therapy. Implications for nursing practice Nursing professionals who are aware of the efficacy and safety data associated with 90Y ibritumomab tiuxetan can optimize efficacy and educate patients and their caregivers about the regimen.

Original languageEnglish (US)
Pages (from-to)8-13
Number of pages6
JournalSeminars in oncology nursing
Issue numberSUPPL. 1
StatePublished - Feb 2004

ASJC Scopus subject areas

  • Oncology(nursing)


Dive into the research topics of 'Efficacy and safety of radioimmuno-therapy with yttrium 90 ibritumomab tiuxetan (Zevalin)'. Together they form a unique fingerprint.

Cite this